A 48-year-old woman presents with 3 months of progressive proximal muscle weakness and a distinctive photosensitive rash. Examination reveals violaceous erythema and edema of the upper eyelids, and erythematous papules overlying the metacarpophalangeal and interphalangeal joints, as shown in the diagram marked **A**. Laboratory studies show creatine kinase 4,200 U/L (10× normal), and myositis-specific autoantibodies are positive for anti-TIF1-gamma. Given this autoantibody profile and clinical presentation, what is the most appropriate next step in management?

Question

A 48-year-old woman presents with 3 months of progressive proximal muscle weakness and a distinctive photosensitive rash. Examination reveals violaceous erythema and edema of the upper eyelids, and erythematous papules overlying the metacarpophalangeal and interphalangeal joints, as shown in the diagram marked **A**. Laboratory studies show creatine kinase 4,200 U/L (>10× normal), and myositis-specific autoantibodies are positive for anti-TIF1-gamma. Given this autoantibody profile and clinical presentation, what is the most appropriate next step in management?

Accepted Answer

B. Age-appropriate malignancy screening (mammography, colonoscopy, CT chest/abdomen/pelvis) followed by high-dose prednisone and methotrexate. ## Why option 1 is correct

The clinical presentation shown in **A** — heliotrope rash, Gottron papules, proximal weakness, and elevated CK — is classic dermatomyositis. The anti-TIF1-gamma autoantibody is a myositis-specific antibody strongly associated with occult malignancy in adults, particularly when diagnosed after age 40. According to Lundberg ACR/EULAR 2017 classification and Dalakas NEJM 2015, patients with anti-TIF1-gamma dermatomyositis have a 3–6× increased cancer risk, peaking in the year before and 2 years after diagnosis. Therefore, age-appropriate malignancy screening (mammography, gynecologic exam, colonoscopy, CT chest/abdomen/pelvis) is mandatory before or concurrent with immunosuppressive therapy. Concurrent treatment with high-dose prednisone (1 mg/kg/day) and an early steroid-sparing agent such as methotrexate is the standard-of-care immunosuppressive regimen.

## Why each distractor is wrong

- **Option 2**: IVIG and rituximab are reserved for refractory disease or rapidly progressive interstitial lung disease (ILD). Anti-MDA5 antibodies, not anti-TIF1-gamma, are associated with amyopathic DM and rapidly progressive ILD. This patient has no clinical evidence of ILD and does not require this aggressive approach as first-line therapy.
- **Option 3**: Hydroxychloroquine alone is insufficient for systemic dermatomyositis with significant myositis (CK 4,200 U/L). Hydroxychloroquine controls cutaneous manifestations but does not address muscle inflammation. Observation without immunosuppression risks progressive muscle damage and organ involvement.
- **Option 4**: While azathioprine and mycophenolate are valid steroid-sparing agents, they should not be used as monotherapy in newly diagnosed dermatomyositis with high CK and myositis. Moreover, this option omits the critical malignancy screen mandated by the anti-TIF1-gamma profile.

**High-Yield:** Anti-TIF1-gamma in adult-onset dermatomyositis mandates urgent age-appropriate cancer screening; anti-MDA5 mandates aggressive treatment for rapidly progressive ILD.

[cite: Lundberg ACR/EULAR 2017 Classification; Dalakas NEJM 2015; Bolognia Dermatology 5e Ch 42]

Answer

A. Hydroxychloroquine monotherapy with strict photoprotection and observation for 6 weeks

Answer

C. Empiric treatment with azathioprine and mycophenolate without further investigation

Answer

D. Initiation of high-dose intravenous immunoglobulin (IVIG) and rituximab for rapidly progressive interstitial lung disease

Explanation

Why option 1 is correct

Why each distractor is wrong

Practice similar questions

Join our NEET PG community